Role of Bladder Capacity in Assessing the Effectiveness of Antimuscarinic Agents on Nocturia in Patients with Overactive Bladders

Shang Jen Chang, Stephen S D Yang, Yao Chou Tsai, Chia Chang Wu, Cheng Hsing Hsieh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The aim of this study was to evaluate the effectiveness of oxybutynin in the treatment of nocturia in patients with overactive bladders (OAB) and to assess predictive factors for the responses to oxybutynin. Patients and Methods: Patients with symptoms of OAB and nocturia for more than 3 months were enrolled. A 2.5 mg dose of oxybutynin was given twice daily for 1 week after a baseline study that included a self-administered nocturia questionnaire, uroflowmetry, and frequency/volume chart. Outcome analysis included changes in nocturia episodes, uroflowmetry, and post-void residual urine. Patients were stratified according to a nocturia index (Ni), nocturnal polyuria index (NPi), and nocturnal bladder capacity index (NBCi). Results: A total of 59 patients were eligible for analysis. After 1 week of treatment with oxybutynin, the mean number of nocturia episodes had reduced from 2.7 ± 1.3 to 2.3 ± 1.1 (p <0.01). There were no statistically significant differences in the mean reduction of nocturia episodes between the subgroup of patients with NPi ≤ 0.35 and those with NPi > 0.35 (-0.4 vs. -0.3, p = 0.34, ANCOVA). Reduction in number of nocturia episodes was more significant in patients with Ni ≤ 1.5 than in those with Ni > 1.5 (-0.9 vs. -0.2, p = 0.03, ANCOVA), and in patients with NBCi > 2 than in those with NBCi ≤ 2 (-1.1 vs. -0.2, p = 0.01, ANCOVA). Conclusion: Ni and NBCi are good predicting factors for the effects of antimuscarinic agents on nocturia in patients with OAB.

Original languageEnglish
Pages (from-to)304-308
Number of pages5
JournalTzu Chi Medical Journal
Volume20
Issue number4
DOIs
Publication statusPublished - Dec 2008
Externally publishedYes

Fingerprint

Nocturia
Overactive Urinary Bladder
Muscarinic Antagonists
Urinary Bladder
Polyuria

Keywords

  • Antimuscarinic
  • Nocturia
  • Overactive bladder

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Role of Bladder Capacity in Assessing the Effectiveness of Antimuscarinic Agents on Nocturia in Patients with Overactive Bladders. / Chang, Shang Jen; Yang, Stephen S D; Tsai, Yao Chou; Wu, Chia Chang; Hsieh, Cheng Hsing.

In: Tzu Chi Medical Journal, Vol. 20, No. 4, 12.2008, p. 304-308.

Research output: Contribution to journalArticle

Chang, Shang Jen ; Yang, Stephen S D ; Tsai, Yao Chou ; Wu, Chia Chang ; Hsieh, Cheng Hsing. / Role of Bladder Capacity in Assessing the Effectiveness of Antimuscarinic Agents on Nocturia in Patients with Overactive Bladders. In: Tzu Chi Medical Journal. 2008 ; Vol. 20, No. 4. pp. 304-308.
@article{4d27a46f1929455d91393a160c4e9fe2,
title = "Role of Bladder Capacity in Assessing the Effectiveness of Antimuscarinic Agents on Nocturia in Patients with Overactive Bladders",
abstract = "Objective: The aim of this study was to evaluate the effectiveness of oxybutynin in the treatment of nocturia in patients with overactive bladders (OAB) and to assess predictive factors for the responses to oxybutynin. Patients and Methods: Patients with symptoms of OAB and nocturia for more than 3 months were enrolled. A 2.5 mg dose of oxybutynin was given twice daily for 1 week after a baseline study that included a self-administered nocturia questionnaire, uroflowmetry, and frequency/volume chart. Outcome analysis included changes in nocturia episodes, uroflowmetry, and post-void residual urine. Patients were stratified according to a nocturia index (Ni), nocturnal polyuria index (NPi), and nocturnal bladder capacity index (NBCi). Results: A total of 59 patients were eligible for analysis. After 1 week of treatment with oxybutynin, the mean number of nocturia episodes had reduced from 2.7 ± 1.3 to 2.3 ± 1.1 (p <0.01). There were no statistically significant differences in the mean reduction of nocturia episodes between the subgroup of patients with NPi ≤ 0.35 and those with NPi > 0.35 (-0.4 vs. -0.3, p = 0.34, ANCOVA). Reduction in number of nocturia episodes was more significant in patients with Ni ≤ 1.5 than in those with Ni > 1.5 (-0.9 vs. -0.2, p = 0.03, ANCOVA), and in patients with NBCi > 2 than in those with NBCi ≤ 2 (-1.1 vs. -0.2, p = 0.01, ANCOVA). Conclusion: Ni and NBCi are good predicting factors for the effects of antimuscarinic agents on nocturia in patients with OAB.",
keywords = "Antimuscarinic, Nocturia, Overactive bladder",
author = "Chang, {Shang Jen} and Yang, {Stephen S D} and Tsai, {Yao Chou} and Wu, {Chia Chang} and Hsieh, {Cheng Hsing}",
year = "2008",
month = "12",
doi = "10.1016/S1016-3190(08)60055-5",
language = "English",
volume = "20",
pages = "304--308",
journal = "Tzu Chi Medical Journal",
issn = "1016-3190",
publisher = "財團法人中華民國佛教慈濟慈善事業基金會",
number = "4",

}

TY - JOUR

T1 - Role of Bladder Capacity in Assessing the Effectiveness of Antimuscarinic Agents on Nocturia in Patients with Overactive Bladders

AU - Chang, Shang Jen

AU - Yang, Stephen S D

AU - Tsai, Yao Chou

AU - Wu, Chia Chang

AU - Hsieh, Cheng Hsing

PY - 2008/12

Y1 - 2008/12

N2 - Objective: The aim of this study was to evaluate the effectiveness of oxybutynin in the treatment of nocturia in patients with overactive bladders (OAB) and to assess predictive factors for the responses to oxybutynin. Patients and Methods: Patients with symptoms of OAB and nocturia for more than 3 months were enrolled. A 2.5 mg dose of oxybutynin was given twice daily for 1 week after a baseline study that included a self-administered nocturia questionnaire, uroflowmetry, and frequency/volume chart. Outcome analysis included changes in nocturia episodes, uroflowmetry, and post-void residual urine. Patients were stratified according to a nocturia index (Ni), nocturnal polyuria index (NPi), and nocturnal bladder capacity index (NBCi). Results: A total of 59 patients were eligible for analysis. After 1 week of treatment with oxybutynin, the mean number of nocturia episodes had reduced from 2.7 ± 1.3 to 2.3 ± 1.1 (p <0.01). There were no statistically significant differences in the mean reduction of nocturia episodes between the subgroup of patients with NPi ≤ 0.35 and those with NPi > 0.35 (-0.4 vs. -0.3, p = 0.34, ANCOVA). Reduction in number of nocturia episodes was more significant in patients with Ni ≤ 1.5 than in those with Ni > 1.5 (-0.9 vs. -0.2, p = 0.03, ANCOVA), and in patients with NBCi > 2 than in those with NBCi ≤ 2 (-1.1 vs. -0.2, p = 0.01, ANCOVA). Conclusion: Ni and NBCi are good predicting factors for the effects of antimuscarinic agents on nocturia in patients with OAB.

AB - Objective: The aim of this study was to evaluate the effectiveness of oxybutynin in the treatment of nocturia in patients with overactive bladders (OAB) and to assess predictive factors for the responses to oxybutynin. Patients and Methods: Patients with symptoms of OAB and nocturia for more than 3 months were enrolled. A 2.5 mg dose of oxybutynin was given twice daily for 1 week after a baseline study that included a self-administered nocturia questionnaire, uroflowmetry, and frequency/volume chart. Outcome analysis included changes in nocturia episodes, uroflowmetry, and post-void residual urine. Patients were stratified according to a nocturia index (Ni), nocturnal polyuria index (NPi), and nocturnal bladder capacity index (NBCi). Results: A total of 59 patients were eligible for analysis. After 1 week of treatment with oxybutynin, the mean number of nocturia episodes had reduced from 2.7 ± 1.3 to 2.3 ± 1.1 (p <0.01). There were no statistically significant differences in the mean reduction of nocturia episodes between the subgroup of patients with NPi ≤ 0.35 and those with NPi > 0.35 (-0.4 vs. -0.3, p = 0.34, ANCOVA). Reduction in number of nocturia episodes was more significant in patients with Ni ≤ 1.5 than in those with Ni > 1.5 (-0.9 vs. -0.2, p = 0.03, ANCOVA), and in patients with NBCi > 2 than in those with NBCi ≤ 2 (-1.1 vs. -0.2, p = 0.01, ANCOVA). Conclusion: Ni and NBCi are good predicting factors for the effects of antimuscarinic agents on nocturia in patients with OAB.

KW - Antimuscarinic

KW - Nocturia

KW - Overactive bladder

UR - http://www.scopus.com/inward/record.url?scp=56849099313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56849099313&partnerID=8YFLogxK

U2 - 10.1016/S1016-3190(08)60055-5

DO - 10.1016/S1016-3190(08)60055-5

M3 - Article

AN - SCOPUS:56849099313

VL - 20

SP - 304

EP - 308

JO - Tzu Chi Medical Journal

JF - Tzu Chi Medical Journal

SN - 1016-3190

IS - 4

ER -